emjreviews.com1d
New Strategy Enhances PD-1 Therapy in Treatment-Resistant Cancers
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
The American Journal of Managed Care5d
2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
Medscape1d
Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
precisionmedicineonline2d
Cel-Sci to Initiate Phase III Trial of Immunotherapy in PD-L1-Low Head and Neck Cancer
The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.
Targeted Oncology2d
FDA Grants Breakthrough Therapy Status to Petosemtamab/Pembrolizumab in HNSCC
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
BioWorld3d
BA-4415, an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...
Targeted Oncology5d
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2024, as well as ...
Pharmabiz2d
Merus’ petosemtamab receives US FDA breakthrough therapy designation for 1L PD-L1 positive head and neck squamous cell carcinoma
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...